Agomab Therapeutics NV (AGMB)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
AgomAb Therapeutics: High Risk, High Reward Stock
AgomAb Therapeutics offers high-risk, high-reward potential driven by two late-stage immunology drugs targeting large addressable markets. AGMB-129 (Crohn's disease) and AGMB-447 (IPF) have Fast Track and Orphan Drug designations, indicating significant unmet need and regulatory advantages. Strong backing from major pharma players and a high institutional ownership position, AGOM is a potential acquisition target upon successful trial outcomes.
Agomab Therapeutics NV Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| MDP Madelyn D. Purcell Pfizer Inc | 75,000 | $813,750 | $907,897.5 | $94,147.5 | 11.57% |
 Regan O'Neill Burkehill Global Management LP | 35,000 | $367,150 | $427,000 | $59,850 | 16.3% |
 Raymond Debbane Siren, L.L.C. | 411,250 | $4.31M | $4.94M | $625,099.51 | 14.49% |
Agomab Therapeutics NV (AGMB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Agomab Therapeutics NV ever had a stock split?
Agomab Therapeutics NV Profile
| Biotechnology Industry | Healthcare Sector | Tim Knotnerus CEO | NASDAQ (NMS) Exchange | 00860C102 CUSIP |
| BE Country | 62 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company based in Antwerp, Belgium, which specializes in the development of innovative disease-modifying therapies aimed at treating immunology and inflammatory diseases. The company primarily focuses on chronic fibrotic conditions where there are significant unmet medical needs. Established in 2017, AgomAb Therapeutics is committed to advancing its understanding of fibrotic diseases and providing novel therapeutic options to improve patient outcomes.
Products and Services
- Ontunisertib (AGMB-129): An oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1, Ontunisertib is being investigated for its efficacy in treating Fibrostenosing Crohn's disease. Currently, it is in Phase 2a clinical trials, aimed at assessing its safety and effectiveness in addressing this chronic inflammatory condition.
- AGMB-447: This product is an inhaled small molecule inhibitor of ALK5 or TGFßR1 designed for the treatment of idiopathic pulmonary fibrosis (IPF). AGMB-447 is currently undergoing Phase 1 clinical trials, where its pharmacological profile and safety will be evaluated, contributing to the potential for better therapeutic interventions in IPF.
- AGMB-101: A monoclonal antibody that mimics hepatocyte growth factor (HGF), AGMB-101 acts through the stimulation of the MET receptor. This product has shown promising antifibrotic and regenerative activity in preclinical models, making it a potential candidate for treating various fibrotic diseases.
